News EU approves CSL's once-monthly HAE drug Andembry The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.
News CSL preps filings for once-monthly antibody for HAE Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y
News Novo Nordisk partners Amazon on London AI hub Novo Nordisk has joined forces with Amazon Web Services on a project that will lead to the creation of an AI co-innovation hub in London.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
